SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ --
Protein Polymer Technologies, Inc. (OTC Bulletin Board: PPTI), today announced
the receipt of its 1st milestone payment from Genencor International, Inc.
under the worldwide exclusive license agreement established at the end of
2000.  The license grants Genencor the right to use PPTI's proprietary protein
polymer design and production technology for industrial and personal care
product applications, while PPTI continues to retain all rights to its
technology for use in the development and commercialization of medical
products.  The milestone payment became due upon Genencor's incorporation of
the licensed technology into a development program with a partner.
    Genencor International is a world leader in the development and
manufacture of industrial enzymes and other biotechnology products.  Protein
Polymer Technologies, whose internal product focus is primarily medical, holds
the fundamental patents on the design and development of de novo proteins that
in form are highly repetitive polymers with predictable physical and
biological properties.  "This milestone payment reflects not only Genencor's
progress towards commercial products based on our technology, but also our
progress in realizing returns on the full breadth of our technology," said
PPTI's President and Chief Executive Officer, J. Thomas Parmeter.

    Protein Polymer Technologies, Inc., is a San Diego-based company focused
on developing products to improve medical and surgical outcomes.  From its
inception in 1988, PPTI has been a pioneer in protein design and synthesis,
developing an extensive portfolio of proprietary biomaterials.  These
genetically engineered biomaterials are high molecular weight proteins,
processed into products with physical and biological characteristics tailored
to specific clinical performance requirements.  Targeted products include
urethral bulking agents for the treatment of stress urinary incontinence,
dermal augmentation products for cosmetic and reconstructive surgery, surgical
adhesives and sealants, scaffolds for wound healing and tissue engineering,
and depots for local drug delivery.  To date, PPTI has been issued twenty-four
U.S. Patents on its core technology with corresponding issued and pending
patents in key international markets.

    This press release contains forward-looking statements that are based on
management's views and expectations.  Actual results could differ materially
from those expressed here; further, the Company is not obligated to comment
specifically on those differences.  Risks associated with the Company's
activities include raising adequate capital to continue operations scientific
and product development uncertainties, competitive products and approaches,
continuing collaborative partnership interest and funding, regulatory testing
and approvals, and manufacturing scale up.  The reader is encouraged to refer
to the Company's 2001 Annual Report Form 10-KSB and subsequent three 2002
Quarterly Reports Form 10QSB, and other recent filings with the Securities and
Exchange Commission, copies of which are available from the Company, to
further ascertain the risks associated with the above statements.

Link to this page: